Transaction #28812 · Form 4 · 0002115875-26-000007
Connect Biopharma Holdings Ltd · Stock award · Ordinary Shares
Connect Biopharma Holdings Ltd · Transacted September 30, 2026 · Filed October 1, 2026
What does this filing report?
An SEC Form 4 filing for Connect Biopharma Holdings Ltd records a stock award involving Ordinary Shares on September 30, 2026. The reported quantity was 5,000. The filing date is October 1, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001835268
- Security type
- Non-derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 5,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 91,554
- Ownership description
- Not reported
- SEC acceptance time
- Oct 1, 2026, 5:18 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Xanthopoulos Kleanthis Gabriel ↗
Director
CIK 0002115875
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.